Geographic Atrophy: Making An Informed Treatment Choice

With two FDA-approved treatments now available for geographic atrophy, an advanced form of dry age-related macular degeneration, we’ll explore how to navigate treatment options, engage in shared decision-making with your healthcare team, and maximize your eye health. February is Low Vision Awareness Month, so we’ll also discuss support options for those living with vision loss.

Dr. Pamela Weber is presently practicing with Vitreoretinal Consultants of New York which is part of Retina Consultants of America. She is actively involved in research, surgery and patient care. Her special interests include macular degeneration, diabetic retinopathy and ROP (retinopathy of prematurity). She has been the principal investigator for over 40 phase 2 and 3 clinical trials. Her education includes a BSC from McGill University, and a Medical degree from Columbia College of Physicians and Surgeons. She did her ophthalmology residency at New York Eye and Ear Hospital, and her fellowship in vitreoretinal surgery at Harvard University, Mass Eye and Ear. She was a full-time member of the Stony Brook University Ophthalmology and remains an Assistant Professor there.